Mydecine Innovations Group Inc C.MYCO

Alternate Symbol(s): MYCOF

Healthcare Advertising Agencies

Mydecine Innovations Group Inc. is a Canada-based biotechnology company. The Company is engaged in developing medications and therapies to address mental health disorders, such as nicotine addiction and posttraumatic stress disorder (PTSD). The Company conducts research and development on second generation compounds in Canada with a focus on developing and commercializing psychedelic-inspired regulated medicines. The Company has two lead 3,4-Methylenedioxymethamphetamine (MDMA) candidates. The Company is channeling its MYCO-005, MYCO-006, and MYCO-007 families of patent-pending second-generation MDMA and Psilocybin analogs through Applied Pharmaceutical Innovation (API). It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.

CSE:MYCO - Post by User

Mydecine Innovations Group Inc

Bullboard Posts

Comment by SSM0006on Feb 28, 2017 7:35am

118 Views

Post# 25903500

RE:Spinoff ???

From Jan 25, 2017 NR
Spin Out of NHS — The Company expects to complete the spin out of NHS in 2017 with shares being distributed to shareholders of record as of November 30, 2016 as soon as all the steps are completed. This is expected to take place closer to the end of Q1 as the Company is seeking to list NHS on a stock exchange. The required documents and filings are being prepared now.

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload